Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test.
AFP
MALDI-TOF
cancer screening
cirrhosis
machine learning
proteomics
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Jun 2021
22 Jun 2021
Historique:
received:
26
05
2021
revised:
12
06
2021
accepted:
14
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is one of the fastest growing causes of cancer-related death. Guidelines recommend obtaining a screening ultrasound with or without alpha-fetoprotein (AFP) every 6 months in at-risk adults. AFP as a screening biomarker is plagued by low sensitivity/specificity, prompting interest in discovering alternatives. Mass spectrometry-based techniques are promising in their ability to identify potential biomarkers. This study aimed to use machine learning utilizing spectral data and AFP to create a model for early detection. Serum samples were collected from three separate cohorts, and data were compiled to make Development, Internal Validation, and Independent Validation sets. AFP levels were measured, and Deep MALDI
Identifiants
pubmed: 34206321
pii: cancers13133109
doi: 10.3390/cancers13133109
pmc: PMC8268628
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2019 Dec 9;14(12):e0226012
pubmed: 31815946
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Int J Clin Oncol. 2012 Apr;17(2):89-95
pubmed: 21638024
J Pharm Biomed Anal. 2014 Jul;95:245-55
pubmed: 24699369
Am J Gastroenterol. 2006 Mar;101(3):524-32
pubmed: 16542289
J Proteome Res. 2009 Mar;8(3):1293-303
pubmed: 19161326
J Natl Cancer Inst. 2007 Jun 6;99(11):838-46
pubmed: 17551144
Am J Gastroenterol. 2007 Oct;102(10):2196-205
pubmed: 17617202
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Hepatology. 2005 Nov;42(5):1208-36
pubmed: 16250051
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):531-538
pubmed: 30464023
Anal Chem. 1998 Mar 1;70(5):923-30
pubmed: 9511468
Expert Rev Respir Med. 2014 Feb;8(1):1-4
pubmed: 24308656
BMC Cancer. 2017 Jul 6;17(1):472
pubmed: 28683725
PLoS Med. 2014 Apr 01;11(4):e1001624
pubmed: 24691105
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):144-53
pubmed: 24220911
Gastroenterology. 2012 May;142(6):1264-1273.e1
pubmed: 22537432
Hepatol Int. 2008 Mar;2(1):17-30
pubmed: 19669276
Nature. 2003 Mar 13;422(6928):198-207
pubmed: 12634793
Clin Gastroenterol Hepatol. 2016 Jun;14(6):875-886.e6
pubmed: 26775025
Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50
pubmed: 15508101
Mol Med Rep. 2010 Jul-Aug;3(4):589-96
pubmed: 21472284
BMC Cancer. 2018 Mar 20;18(1):310
pubmed: 29558888
Cancer Immunol Res. 2018 Jan;6(1):79-86
pubmed: 29208646
BMC Bioinformatics. 2019 Jun 13;20(1):325
pubmed: 31196002
Clin Cancer Res. 2020 Oct 1;26(19):5188-5197
pubmed: 32631957
Hepat Oncol. 2017 Oct;4(4):111-122
pubmed: 30191058
Clin Chem Lab Med. 2010 Sep;48(9):1319-26
pubmed: 20509833
Abdom Radiol (NY). 2018 Jan;43(1):41-55
pubmed: 28936543
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Clin Cancer Res. 2008 Jan 15;14(2):470-7
pubmed: 18223221
J Proteomics. 2010 Jan 3;73(3):537-51
pubmed: 19782778
Cancer Manag Res. 2018 Jul 10;10:1947-1958
pubmed: 30022853
Front Genet. 2020 Jan 10;10:1306
pubmed: 31998366
Cancer. 2001 Feb 1;91(3):561-9
pubmed: 11169939
Dig Liver Dis. 2018 Nov;50(11):1115-1123
pubmed: 30217732